Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 15.0

Eligibility Criteria:
Inclusion Criteria:~* Group 1 (HIV-uninfected):~  * Adult males and females, age 18 to 65~ * Amenable to HIV risk reduction counseling and agrees to maintaining behavior consistent with low risk of HIV exposure;~ * If a sexually active male or female, participating in sexual activity that could lead to pregnancy, agrees to use an effective method of contraception throughout the study.~* Groups 2-5 (HIV-infected):~  * Age 18 to 65~ * HIV infection confirmed by ELISA and immunoblot~ * Groups 2A-D - on ART with HIV-1 plasma RNA levels below 100,000 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA level between 2,000-100,000 copies/ml by standard assays on 2 occasions at least 1 week apart;~ * Group 2E - Untreated HIV-infected (not on ART for at least 8 weeks): HIV-1 RNA plasma levels between 2,000 - 100,000 copies/ml;~ * Group 3 - Untreated HIV controllers (not on ART for at least 8 weeks): HIV-1 RNA plasma level of \< 2,000 copies/ml by standard assays, on 2 occasions, at least 1 week apart, and ART-naive.~ * Group 4 - ART treated with HIV-1 RNA plasma level of \> 20 copies/ml by standard assays on 2 occasions, at least 1 week apart, while on combination antiretroviral therapy;~ * Groups 5A and 5B - ART treated with HIV-1 RNA plasma level of \< 20 copies/ml by standard assays on 2 occasions, at least 1 week apart, while on combination antiretroviral therapy;~ * Current CD4 cell count \> 300 cells/µl~ * If sexually active male and female, participating in sexual activity that could lead to pregnancy, agrees to use an effective method of contraception throughout the study.~Exclusion criteria:~* Group 1 (HIV-uninfected):~  * Confirmed HIV-1 or HIV-2 infection;~ * History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months;~ * Any clinically significant acute or chronic medical condition that in the opinion of the investigator would preclude participation;~ * Within the 12 months prior to enrollment, the volunteer has a history of sexually transmitted disease;~ * Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);~ * Laboratory abnormalities in the parameters listed below:~    * Absolute neutrophil count ≤ 2,000~   * Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male~   * Platelet count ≤ 140,000~   * ALT ≥ 1.25 x ULN~   * AST ≥ 1.25 x ULN~   * Total bilirubin ≥ 1.1 ULN~   * Creatinine ≥ 1.1 x ULN~   * Coagulation parameters (PT, PTT, INR) ≥ 1.1 x ULN~ * Pregnancy or breastfeeding;~ * Any vaccination within 14 days prior to 3BNC117 administration;~ * Receipt of any experimental HIV vaccine in the past or monoclonal antibody therapy of any kind in the past;~ * Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.~* Groups 2-5 (HIV-infected):~  * History of AIDS-defining illness~ * History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months;~ * Any clinically significant acute or chronic medical condition, other than HIV infection, that in the opinion of the investigator would preclude participation;~ * Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);~ * Laboratory abnormalities in the parameters listed below:~    * Absolute neutrophil count ≤ 1,300~   * Hemoglobin ≤ 10 gm/dL~   * Platelet count ≤ 125,000~   * ALT ≥ 2.0 x ULN~   * AST ≥ 2.0 x ULN~   * Total bilirubin ≥ 1.1 ULN~   * Creatinine ≥ 1.1 x ULN~   * Coagulation parameters ≥ 1.1 x ULN;~ * Current antiretroviral regimen includes either maraviroc or enfuvirtide;~ * Pregnancy or breastfeeding;~ * Any vaccination within 14 days prior to 3BNC117 administration;~ * Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past;~ * Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1A (Type: EXPERIMENTAL): HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117
- Groups 1B (Type: EXPERIMENTAL): HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
- Group 1C (Type: EXPERIMENTAL): HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
- Group 1D (Type: EXPERIMENTAL): HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
- Group 1E (Type: EXPERIMENTAL): HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
- Group 1F (Type: EXPERIMENTAL): HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
- Group 2A (Type: EXPERIMENTAL): HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117
- Group 2B (Type: EXPERIMENTAL): HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
- Group 2C (Type: EXPERIMENTAL): HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
- Group 2D (Type: EXPERIMENTAL): HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
- Group 2E (Type: EXPERIMENTAL): HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
- Group 3 (Type: EXPERIMENTAL): HIV-infected individuals off ART, VL \< 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
- Group 4 (Type: EXPERIMENTAL): HIV-infected individuals on ART, VL \< 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
- Group 5A (Type: EXPERIMENTAL): HIV-infected individuals on ART, VL \< 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
- Group 5B (Type: EXPERIMENTAL): HIV-infected individuals on ART, VL \< 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete